Natco Pharma gains on launching first generic version of Pomalyst Capsules in Australian market

10 Nov 2022 Evaluate

Natco Pharma is currently trading at Rs. 617.00, up by 3.80 points or 0.62% from its previous closing of Rs. 613.20 on the BSE.

The scrip opened at Rs. 609.05 and has touched a high and low of Rs. 617.35 and Rs. 609.05 respectively. So far 1317 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 942.15 on 17-Jan-2022 and a 52 week low of Rs. 582.75 on 21-Oct-2022.

Last one week high and low of the scrip stood at Rs. 628.80 and Rs. 609.05 respectively. The current market cap of the company is Rs. 11259.21 crore.

The promoters holding in the company stood at 48.80%, while Institutions and Non-Institutions held 25.97% and 25.23% respectively.

Natco Pharma has launched first generic version of Pomalyst (Pomalidomide) Capsules in 1,2,3,4 mg strengths in the Australian market. The product was launched by NATCO’s commercial partner Juno Pharmaceuticals. Pomalidomide is prescribed for treatment of Multiple Myeloma and Kaposi Sarcoma. Pomalyst registered sales of $35.6 million in the Australian market for the year ending March 31, 2022 as per industry sales data.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.


Natco Pharma Share Price

908.10 -8.15 (-0.89%)
26-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1269.05
Cipla 1505.05
Zydus Lifesciences 911.50
Lupin 2112.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×